Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
-
New eye implant could drastically reduce injections for diabetic vision loss
Disease control Recruiting nowThis study is testing a new, long-acting eye implant called EYP-1901 against the standard aflibercept injections for diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The main goal is to see if the implant can control the disease just as well wh…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New eye implant could drastically reduce injections for diabetic vision loss
Disease control Recruiting nowThis study is testing if a new, long-acting eye implant called EYP-1901 can control vision loss from diabetic macular edema as well as standard aflibercept injections, but with far fewer treatments. It will involve about 240 adults with the condition, comparing the implant's effe…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC